Literature DB >> 9704340

Small intestinal stromal tumors: a clinicopathologic study of 31 tumors.

M S Chang1, G Choe, W H Kim, Y I Kim.   

Abstract

The biologic behavior of gastrointestinal stromal tumors is difficult to predict, and they can be best studied in a site-specific fashion. The aims of this study are to analyze the clinicopathologic parameters and assess the prognostic value of p53 (DO-7) and Ki-67 (MIB-1) immunoreactivities in small intestinal stromal tumors (SIST). The histopathologic features of 31 SIST were assessed and categorized into two groups as follows. Group A (clinically aggressive) in which death due to tumor, metastasis, recurrence or relapsed melena were seen (n = 15) and group B (clinically benign; n = 16). For both groups, the period of follow-up was 30-144 months. p53 overexpression was observed in four tumors (31%) in group A, and in none in group B. For groups A and B, the mean Ki-67 index was 16.8 +/- 12.5 and 8.4 +/- 12.6, respectively. Statistical analysis revealed that the significant predictors of malignancy were high cellularity (odds ratio (OR) = 999; 95% confidence interval (CI) = 0-999); p53 overexpression (OR = 999; CI = 0-999); size of tumor > or = 5 cm (OR = 18.0; CI = 1.9-171.9); > or = 5 mitoses/50 high-power fields (HPF) (OR = 17.1; CI = 1.8-165.9); pleomorphism (OR = 17.1; CI = 1.8-165.9); and necrosis (OR = 11.9; CI = 2.2-65.1; P < 0.05). High Ki-67 index (> or = 8.4) had a marginal impact on risk (OR = 4.1; CI = 0.8-20.2; P = 0.08). In conclusion, high cellularity, p53 overexpression, size of tumor > or = 5 cm, > or = 5 mitoses/50 HPF, pleomorphism and necrosis are important parameters for the prediction of malignancy in SIST.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9704340     DOI: 10.1111/j.1440-1827.1998.tb03916.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  7 in total

1.  Perforated Meckel's diverticulum presenting as a gastrointestinal stromal tumor: a case report.

Authors:  Martina Hager; Hans Maier; Martin Eberwein; Paul Klingler; Christian Kolbitsch; Werner Tiefenthaler; Gregor Mikuz; Patrizia Lucia Moser
Journal:  J Gastrointest Surg       Date:  2005 Jul-Aug       Impact factor: 3.452

2.  Prognostic factors and outcome of resected patients with gastrointestinal stromal tumors of small intestine.

Authors:  Rong Fan; Jie Zhong; Zhen-ting Wang; Li-fen Yu; Yong-hua Tang; Wei-guo Hu; Yan-bo Zhu; Xiao-long Jin
Journal:  Med Oncol       Date:  2010-10-08       Impact factor: 3.064

3.  A gastrointestinal stromal tumour presenting incidentally with haemorrhage and perforation associated with a Meckel's diverticulum: a case report.

Authors:  Richard Woolf; Natalie Blencowe; Karim Muhammad; David Paterson; Geoff Pye
Journal:  J Med Case Rep       Date:  2009-07-23

4.  Predictive value of p53 expression in the risk of malignant gastrointestinal stromal tumors: Evidence from 19 studies.

Authors:  Liang Zong; Ping Chen; Jian Jiang; Lei Wang; Qing Guo Li
Journal:  Exp Ther Med       Date:  2011-10-19       Impact factor: 2.447

5.  Clinical outcomes of tumor bleeding in duodenal gastrointestinal stromal tumors: a 20-year single-center experience.

Authors:  Gyu Young Pih; Ji Yong Ahn; Ji Young Choi; Hee Kyong Na; Jeong Hoon Lee; Kee Wook Jung; Do Hoon Kim; Kee Don Choi; Ho June Song; Gin Hyug Lee; Hwoon-Yong Jung
Journal:  Surg Endosc       Date:  2020-03-13       Impact factor: 4.584

6.  Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate.

Authors:  Ting-Jung Wu; Li-Yu Lee; Chun-Nan Yeh; Pei-Yu Wu; Tzu-Chieh Chao; Tsann-Long Hwang; Yi-Yin Jan; Miin-Fu Chen
Journal:  BMC Gastroenterol       Date:  2006-10-24       Impact factor: 3.067

7.  Prognostic value of tumor necrosis in gastrointestinal stromal tumor: A meta-analysis.

Authors:  Mengshi Yi; Lin Xia; Yan Zhou; Xiaoting Wu; Wen Zhuang; Yi Chen; Rui Zhao; Qianyi Wan; Liang Du; Yong Zhou
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.